Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young,Andrea Marshall,Jenny Thirlwall,Oliver Chapman,Anand Lokare,Catherine Hill,Danielle Hale,Janet A. Dunn,Gary H. Lyman,Charles Hutchinson,Peter MacCallum,Ajay K. Kakkar,FD Richard Hobbs,Stavros Petrou,Jeremy Dale,Christopher J. Poole,Anthony Maraveyas,Mark Levine +17 more
TLDR
Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin, and safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB).Abstract:
PurposeVenous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer.Patient and MethodsIn this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within ±...read more
Citations
More filters
Journal ArticleDOI
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)
Stavros Konstantinides,Guy Meyer,Cecilia Becattini,Héctor Bueno,Geert-Jan Geersing,Veli-Pekka Harjola,Menno V. Huisman,Marc Humbert,Catriona Jennings,David Jiménez,Nils Kucher,Irene M. Lang,Mareike Lankeit,Roberto Lorusso,Lucia Mazzolai,Nicolas Meneveau,Fionnuala Ní Áinle,Paolo Prandoni,Piotr Pruszczyk,Marc Philip Righini,Adam Torbicki,Eric Van Belle,José Luis Zamorano +22 more
TL;DR: Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
Journal ArticleDOI
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)
Stavros Konstantinides,Guy Meyer,Cecilia Becattini,Héctor Bueno,Geert-Jan Geersing,Veli-Pekka Harjola,Menno V. Huisman,Marc Humbert,Catriona Jennings,David Jiménez,Nils Kucher,Irene M. Lang,Mareike Lankeit,Roberto Lorusso,Lucia Mazzolai,Nicolas Meneveau,Fionnuala Ní Áinle,Paolo Prandoni,Piotr Pruszczyk,Marc Philip Righini,Adam Torbicki,Eric Van Belle,José Luis Zamorano +22 more
TL;DR: New ESCardio Guidelines for the Diagnosis and Management of Acute PulmonaryEmbolism developed in collaboration with EuroRespSoc are available.
Journal ArticleDOI
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier,Karim Abou-Nassar,Ranjeeta Mallick,Vicky Tagalakis,Sudeep Shivakumar,Ariah Schattner,Philip Kuruvilla,Danny Hill,Silvana Spadafora,Katerine Marquis,Mateya Trinkaus,Anna Tomiak,Agnes Y.Y. Lee,Peter L. Gross,Alejandro Lazo-Langner,Robert El-Maraghi,Glenwood D. Goss,Grégoire Le Gal,David J. Stewart,Tim Ramsay,Marc A. Rodger,Debra Witham,Philip S. Wells,Avert Investigators +23 more
TL;DR: Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate‐to‐high‐risk ambulatory patients with cancer who were starting chemotherapy.
Journal ArticleDOI
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Dominique Farge,Dominique Farge,Corinne Frere,Jean M. Connors,Cihan Ay,Alok A. Khorana,Andrés Muñoz,Benjamin Brenner,Ajay K. Kakkar,Hanadi Rafii,Susan Solymoss,Dialina Brilhante,Manuel Monreal,Henri Bounameaux,Ingrid Pabinger,James D. Douketis,Walter Ageno,Fernando Ajauro,Kamal R. Al-Aboudi,Thierry Alcindor,Thierry André,Pantep Angchaisuksiri,Darko Antic,Juan I. Arcelus,Eric Assenat,Kenneth A. Bauer,Ali Bazarbachii,I. Benzidia,Jan Beyer-Westendorf,Viktoria Bitsadze,Dorit Blickstein,Mark Blostein,Isabel Bogalho,Barbara Bournet,Patricia Casais,Antoine F. Carpentier,Gabriela Cesarman-Maus,Joydeep Chakbrabartty,Hugo A. Clemente,Jérôme Connault,Ludovic Doucet,Cécile Durant,Joseph Emmerich,Anna Falanga,Clemens Feistritzer,Carme Font,Charles W. Francis,Enrique Gallardo,Thomas Gary,Jean-Christophe Gris,Cecilia Guillermo,A. Hij,Russel D. Hull,Takayuki Ikezoe,Luis Jara-Palomares,Nigel S. Key,Jamilya Khrizroeva,Maral Koolian,Florian Langer,Ramón Lecumberri,Lai Heng Lee,Howard A. Liebman,Luisa Lopes Dos Santos,Duarte Henrique Machado,Isabelle Madelaine,Alexander Makatsariya,Mario Mandalà,Anthony Marayevas,Zora Marjanovic,Christine Marosi,Ellis Martin,Luis Meillon,Emmanuel Messas,Antonio Moreira,Ahmet M. Demir,Arlette Ndour,Michel Nguessan,Remedios Otero-Candelera,Vanessa Pachon Olmos,Ana Pais,Florian Posch,Matthias Preusser,Hanno Riess,Marc Philip Righini,Cynthia Rothschild,Andre Roussin,José Antonio Rueda-Camino,Pedro Ruiz-Artacho,Sanjith Saseedharan,Ali Shamseddine,Gerald A. Soff,Hans Stricker,Vicky Tagalakis,Ali T. Taher,Toutou Toussaint,Javier Trujillo-Santos,Stéphane Villiers,Raymond S.M. Wong,Norizaku Yamada +98 more
TL;DR: The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods.
Journal ArticleDOI
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen,Michael Weller,Eudocia Q. Lee,Brian M. Alexander,Jill S. Barnholtz-Sloan,Floris P. Barthel,Tracy T. Batchelor,Ranjit S. Bindra,Susan M. Chang,E. Antonio Chiocca,Timothy F. Cloughesy,John DeGroot,Evanthia Galanis,Mark R. Gilbert,Monika E. Hegi,Craig Horbinski,Raymond Y. Huang,Andrew B. Lassman,Emilie Le Rhun,Michael Lim,Minesh P. Mehta,Ingo K. Mellinghoff,Giuseppe Minniti,David Nathanson,Michael Platten,Matthias Preusser,Patrick Roth,Marc Sanson,David Schiff,Susan C Short,Martin J B Taphoorn,Joerg C. Tonn,Jonathan Tsang,Roel G.W. Verhaak,Andreas von Deimling,Wolfgang Wick,Gelareh Zadeh,David A. Reardon,Kenneth Aldape,Martin J. van den Bent +39 more
TL;DR: Novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies and viral therapies will be reviewed, as well as the current challenges and future directions for research.
References
More filters
Journal ArticleDOI
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators
Ted Gooley,Ted Gooley,Wendy M. Leisenring,Wendy M. Leisenring,John Crowley,John Crowley,Barry E. Storer,Barry E. Storer +7 more
TL;DR: A representation of each estimate in a manner not ordinarily seen is presented, each representation utilizing the concept of censored observations being 'redistributed to the right' to allow a more intuitive understanding of each estimates.
Journal ArticleDOI
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli,Harry R. Buller,Alexander T. Cohen,Madelyn Curto,Alexander Gallus,Margot Johnson,Urszula Masiukiewicz,Raphael Pak,John F. Thompson,Gary E. Raskob,Jeffrey I. Weitz +10 more
TL;DR: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding.
Journal ArticleDOI
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
Paolo Prandoni,Anthonie W. A. Lensing,Andrea Piccioli,Enrico Bernardi,Paolo Simioni,Bruno Girolami,Antonio Marchiori,Paola Sabbion,Martin H. Prins,Franco Noventa,Antonio Girolami +10 more
TL;DR: Possibility for improvement using the current paradigms of anticoagulation seem limited and new treatment strategies should be developed, as cancer patients with venous thrombosis are more likely to develop recurrent thromboembolic complications and major bleeding during anticoaggerant treatment than those without malignancy.
Journal ArticleDOI
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Buller,Hervé Decousus,Michael A. Grosso,Saskia Middeldorp,Martin H. Prins,Gary E. Raskob,Sebastian Schellong,Annelise Segers,Minggao Shi,Peter Verhamme,Phil Wells +10 more
TL;DR: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism.
Journal ArticleDOI
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman,Ajay K. Kakkar,Samuel Z. Goldhaber,Sebastian Schellong,Henry Eriksson,Patrick Mismetti,Anita Vedel Christiansen,Jeffrey Friedman,Florence Le Maulf,Nuala Peter,Clive Kearon +10 more
TL;DR: Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE.
Related Papers (5)
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more